Nuvalent/$NUVL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Nuvalent
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
Ticker
$NUVL
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
162
ISIN
US6707031075
Website
Nuvalent Metrics
BasicAdvanced
$5.9B
-
-$4.41
1.42
-
Price and volume
Market cap
$5.9B
Beta
1.42
52-week high
$104.04
52-week low
$55.54
Average daily volume
553K
Financial strength
Current ratio
14.481
Quick ratio
14.303
Profitability
Effective tax rate (TTM)
-0.18%
Management effectiveness
Return on assets (TTM)
-22.23%
Return on equity (TTM)
-35.69%
Valuation
Price to book
5.82
Price to tangible book (TTM)
5.82
Price to free cash flow (TTM)
-27.494
Free cash flow yield (TTM)
-3.64%
Free cash flow per share (TTM)
-298.50%
Growth
Earnings per share change (TTM)
81.96%
3-year earnings per share growth (CAGR)
36.68%
What the Analysts think about Nuvalent
Analyst ratings (Buy, Hold, Sell) for Nuvalent stock.
Bulls say / Bears say
Nuvalent's lead drug candidates, zidesamtinib and NVL-655, are progressing through Phase 2 trials, with pivotal data expected in 2025, potentially leading to regulatory approvals and market entry. (Investing.com)
Analysts project significant revenue growth for Nuvalent, estimating revenues of $205 million in 2026, growing to $4.5 billion by 2032, indicating substantial market potential. (Investing.com)
Nuvalent's focus on developing brain-penetrant tyrosine kinase inhibitors addresses a critical need in treating non-small cell lung cancer with brain metastases, potentially offering a competitive advantage. (Investing.com)
Nuvalent is currently operating at a loss, with an EBITDA of -$141.48 million and projected negative earnings per share for FY2025, indicating financial challenges common in clinical-stage biotech companies. (Investing.com)
The oncology market, particularly for non-small cell lung cancer treatments, is highly competitive, posing risks from established players and emerging therapies that could impact Nuvalent's market share. (Investing.com)
Nuvalent's recent secondary share offering of over 5.3 million shares at $56 each may lead to stock dilution, potentially affecting existing shareholders' value. (The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 10 Jul 2025.
Nuvalent Financial Performance
Revenues and expenses
Nuvalent Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Nuvalent stock?
Nuvalent (NUVL) has a market cap of $5.9B as of July 11, 2025.
What is the P/E ratio for Nuvalent stock?
The price to earnings (P/E) ratio for Nuvalent (NUVL) stock is 0 as of July 11, 2025.
Does Nuvalent stock pay dividends?
No, Nuvalent (NUVL) stock does not pay dividends to its shareholders as of July 11, 2025.
When is the next Nuvalent dividend payment date?
Nuvalent (NUVL) stock does not pay dividends to its shareholders.
What is the beta indicator for Nuvalent?
Nuvalent (NUVL) has a beta rating of 1.42. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.